Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma

Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma

US Patent 11078275 · Granted Aug 3, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Compound that specifically binds to KIR3DL2 for use in the treatment of peripher2024
Compound that specifically binds to KIR3DL2 for use in the treatment of peripher2024
Compound that specifically binds to KIR3DL2 for use in the treatment of peripher2024
Treatment of peripheral T cell lymphoma2024
Treatment of peripheral T cell lymphoma2024
Treatment of peripheral T cell lymphoma2024
Treatment with anti-KIR3DL2 agents2024
KIR3DL2 binding agents2024
Methods for detecting tissue infiltrating NK cells2020
Mica binding agents2020
KIR3DL2 binding agents2020
Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma2019